RESUMEN
BACKGROUND: Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on non-nucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics. METHODS: We conducted a prospective cohort study of PWH ≥18 years who were transitioned from NNRTI-based ART to TLD. Study visits were conducted on the day of TLD transition and 24- and 48- weeks later. The primary endpoint was viral suppression (<200â copies/mL) at 48-weeks. We collected blood for retrospective viral load (VL) assessment and conducted genotypic resistance tests for specimens with VL >500â copies/mL. RESULTS: We enrolled 500 participants (median age of 47 years; 41% women). At 48-weeks after TLD transition, 94% of participants were in care with a VL <200â copies/mL (n = 469/500); 2% (n = 11/500) were lost from care or died; and only 2% (n = 9/500) had a VL >500â copies/mL. No incident resistance to DTG was identified. Few participants (2%, n = 9/500) discontinued TLD due to adverse events. CONCLUSIONS: High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region.
RESUMEN
BACKGROUND: Large language models (LLMs) that can efficiently screen and identify studies meeting specific criteria would streamline literature reviews. Additionally, those capable of extracting data from publications would enhance knowledge discovery by reducing the burden on human reviewers. METHODS: We created an automated pipeline utilizing OpenAI GPT-4 32 K API version "2023-05-15" to evaluate the accuracy of the LLM GPT-4 responses to queries about published papers on HIV drug resistance (HIVDR) with and without an instruction sheet. The instruction sheet contained specialized knowledge designed to assist a person trying to answer questions about an HIVDR paper. We designed 60 questions pertaining to HIVDR and created markdown versions of 60 published HIVDR papers in PubMed. We presented the 60 papers to GPT-4 in four configurations: (1) all 60 questions simultaneously; (2) all 60 questions simultaneously with the instruction sheet; (3) each of the 60 questions individually; and (4) each of the 60 questions individually with the instruction sheet. RESULTS: GPT-4 achieved a mean accuracy of 86.9% - 24.0% higher than when the answers to papers were permuted. The overall recall and precision were 72.5% and 87.4%, respectively. The standard deviation of three replicates for the 60 questions ranged from 0 to 5.3% with a median of 1.2%. The instruction sheet did not significantly increase GPT-4's accuracy, recall, or precision. GPT-4 was more likely to provide false positive answers when the 60 questions were submitted individually compared to when they were submitted together. CONCLUSIONS: GPT-4 reproducibly answered 3600 questions about 60 papers on HIVDR with moderately high accuracy, recall, and precision. The instruction sheet's failure to improve these metrics suggests that more sophisticated approaches are necessary. Either enhanced prompt engineering or finetuning an open-source model could further improve an LLM's ability to answer questions about highly specialized HIVDR papers.
Asunto(s)
Infecciones por VIH , Humanos , Reproducibilidad de los Resultados , Infecciones por VIH/tratamiento farmacológico , PubMed , Publicaciones/estadística & datos numéricos , Publicaciones/normas , Almacenamiento y Recuperación de la Información/métodos , Almacenamiento y Recuperación de la Información/normas , Programas InformáticosRESUMEN
BACKGROUND: Despite the availability of various effective antiretroviral (ARV) drugs, human immunodeficiency virus (HIV) infection has come with HIV drug resistance (HIVDR), which compromises its effectiveness in reducing HIV-related morbidity, mortality, and transmission. The emergence of transmitted (TDR) and acquired HIVDR (ADR) among antiretroviral therapy (ART)-naïve and experienced individuals have been reported in several Indonesian regions. Therefore, continuous HIVDR surveillance is needed in Indonesia, especially in Surabaya, which is identified as having the highest prevalence of HIV infection in East Java; thus, this study aimed to identify the emergence of TDR and ADR among people living with HIV/acquired immune deficiency syndrome (AIDS) (PLWHA). METHODS: Fifty-eight PLWHA infected with HIV type 1 (HIV-1), comprising 21 and 37 ART-naïve and experienced individuals were enrolled in this study, respectively. Blood samples collected from study participants were subjected to genotypic analysis, mainly towards the pol gene encoding protease (PR gene) and reverse transcriptase (RT gene) of HIV-1. RESULTS: Seventeen PR and 21 RT genes were successfully amplified and sequenced from 29 samples. HIV-1 subtyping revealed CRF01_AE as the most dominant subtype (24/29; 82.76%), followed by subtype B (3/29; 10.34%). Uncommon subtypes, including subtype D and a recombinant containing subtypes B and G genomic fragments, were also identified. TDR for PR inhibitors was not detected; however, TDR and ADR for RT inhibitors were identified in 11.11% and 41.67% of samples, respectively. Two amino acid insertions at position 69 of the RT gene (69ins), a previously never-reported mutation in Indonesia, were identified in this study. CONCLUSION: Both TDR and ADR have emerged among PLWHA residing in Surabaya, East Java, Indonesia. Uncommon drug-resistance mutations and subtypes were identified in this study. These situations might hamper ART efficacy and treatment success. Continuous surveillance of HIVDR is necessary to monitor both TDR and ADR in Indonesia.
Asunto(s)
Farmacorresistencia Viral , Genotipo , Infecciones por VIH , VIH-1 , Humanos , Indonesia/epidemiología , Farmacorresistencia Viral/genética , Masculino , Femenino , Adulto , VIH-1/genética , VIH-1/efectos de los fármacos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Persona de Mediana Edad , Fármacos Anti-VIH/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Adulto Joven , MutaciónRESUMEN
The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated, while ensuring data security and privacy for patient information. To address these challenges, here we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short reads, FASTA, and Sanger ab1.seq files.
RESUMEN
BACKGROUND: Tackling HIV drug resistance is one of major challenges for ending AIDS epidemic, but the elevated expense of cutting-edge genomics hampers the advancement of HIV genotype testing for clinical care. METHODS: We developed a HIV genotype testing pipeline that centers on a cost-efficient portable Nanopore sequencer. Accuracy verification was conducted through comparison with parallel data obtained via fixed-site Pacbio sequencing. Our complete pol-gene sequencing strategy coupled with portable high-throughput sequencing was applied to identify drug resistance mutations across 58 samples sourced from the ART-treated Los Angeles General Medical Center Rand Schrader Clinic (LARSC) cohort (7 samples from 7 individuals) and the ART-naïve Center for HIV/AIDS Vaccine Immunology (CHAVI) cohort (51 samples from 38 individuals). RESULTS: A total of 472 HIV consensus sequences, each tagged with a unique molecular identifier, were produced from over 1.4 million bases acquired through portable Nanopore sequencing, which matched those obtained independently via Pacbio sequencing. With this desirable accuracy, we first documented the linkage of multidrug cross-resistance mutations across Integrase Strand Transfer inhibitors (INSTIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from an individual failing a second-generation INSTI regimen. By producing more than 500 full-length HIV pol gene sequences in a single portable sequencing run, we detected Protease Inhibitor (PI), Nucleoside Reverse Transcriptase Inhibitor (NRTI), NNRTI and INSTI resistance mutations. All drug resistance mutations identified through portable sequencing were cross-validated using fixed-site Pacbio sequencing. CONCLUSIONS: Our accurate and affordable HIV drug resistance testing solution is adaptable for both individual patient care and large-scale surveillance initiatives.
Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , Inhibidores de Integrasa VIH , Integrasa de VIH , VIH-1 , Secuenciación de Nanoporos , Humanos , Infecciones por VIH/tratamiento farmacológico , VIH-1/genética , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Fármacos Anti-VIH/farmacología , Fármacos Anti-VIH/uso terapéutico , Genotipo , Inhibidores de Integrasa VIH/uso terapéutico , Mutación , Resistencia a Medicamentos , Farmacorresistencia Viral/genética , Integrasa de VIH/genéticaRESUMEN
Background: The successful detection of drug-resistance mutations (DRMs) in HIV-1 infected patients has improved the management of HIV infection. Next-generation sequencing (NGS) to detect low-frequency mutations is predicted to be useful for efficiently testing minority drug resistance mutations, which could contribute to virological failure. This study employed Sanger sequencing and NGS to detect and compare minority and majority drug resistance mutations in HIV-1 strains in treatment-naive patients from Ghana. Method: From a previous study, 20 antiretroviral therapy (ART)-naive participants were selected for a cross-sectional study. Sanger sequencing and NGS techniques were used to detect the majority and minority HIV drug resistance (HIVDR) mutations, respectively, in the protease (PR) and partial reverse transcriptase (RT) genes. NGS detected mutations at 1 % and 5 % frequencies and Sanger sequencing at ≥20 % frequencies. The sequences obtained from NGS and Sanger sequencing platforms were submitted to the Stanford HIV drug resistance database for subtyping, mutation identification, and interpretations. Results: Sequences from the twenty participants where the CRF02_AG was the predominant strain (16, 80 %) were analyzed. NGS detected 25 mutations in the RT and PR genes, compared to 21 mutations by Sanger sequencing. Minority DRMs were detected at the prevalence of 55.0 % with NGS against 35 % DRMs by Sanger sequencing. One of the patients had eight different HIVDR variants, with two minority variants. These mutations were directed against PI (K20I and D30DN), NNRTI (Y181C, M23LM and V108I) and NRTI (K65R, M184I, and D67N). Conclusion: The study affirms the usefulness of genomic sequencing for drug resistance testing in HIV. It further shows that Sanger sequencing alone may not be adequate to detect mutations and that NGS capacity should be developed and deployed in the Ghanaian clinical settings for patients living with HIV.
RESUMEN
Background: Approximately 30,000 non-citizens are living with HIV in Botswana, all of whom as of 2020 are eligible to receive free antiretroviral treatment (ART) within the country. We assessed the prevalence of HIV-1 mutational profiles [pre-treatment drug resistance (PDR) and acquired drug resistance (ADR)] among treatment-experienced (TE) and treatment-naïve (TN) non-citizens living with HIV in Botswana. Methods: A total of 152 non-citizens living with HIV were enrolled from a migrant HIV clinic at Independence Surgery, a private practice in Botswana from 2019-2021. Viral RNA isolated from plasma samples were genotyped for HIV drug resistance (HIVDR) using Sanger sequencing. Major known HIV drug resistance mutations (DRMs) in the pol region were determined using the Stanford HIV Drug Resistance Database. The proportions of HIV DRMs amongst TE and TN non-citizens were estimated with 95% confidence intervals (95% CI) and compared between the two groups. Results: A total of 60/152 (39.5%) participants had a detectable viral load (VL) >40 copies/mL and these were included in the subsequent analyses. The median age at enrollment was 43 years (Q1, Q3: 38-48). Among individuals with VL > 40 copies/mL, 60% (36/60) were treatment-experienced with 53% (19/36) of them on Atripla. Genotyping had a 62% (37/60) success rate - 24 were TE, and 13 were TN. A total of 29 participants (78.4, 95% CI: 0.12-0.35) had major HIV DRMs, including at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) associated DRM. In TE individuals, ADR to any antiretroviral drug was 83.3% (20/24), while for PDR was 69.2% (9/13). The most frequent DRMs were nucleoside reverse transcriptase inhibitors (NRTIs) M184V (62.1%, 18/29), NNRTIs V106M (41.4%, 12/29), and K103N (34.4%, 10/29). No integrase strand transfer inhibitor-associated DRMs were reported. Conclusion: We report high rates of PDR and ADR in ART-experienced and ART-naïve non-citizens, respectively, in Botswana. Given the uncertainty of time of HIV acquisition and treatment adherence levels in this population, routine HIV-1C VL monitoring coupled with HIVDR genotyping is crucial for long-term ART success.
RESUMEN
BACKGROUND: In vitro passage experiments are crucial to the development of antiretroviral (ARV) drugs. METHODS: We created an online database containing data from 102 published studies in which HIV-1 or HIV-2 was cultured with increasing concentrations of the FDA-approved nucleoside RT inhibitors (NRTIs), nonnucleoside RT inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), protease inhibitors (PIs), capsid inhibitor (CAI) lenacapavir, and nucleoside RT translocation inhibitor (NRTTI) islatravir. We summarized the mutations selected in the subset of passage experiments with NRTIs lamivudine (3TC), emtricitabine (FTC), abacavir (ABC), tenofovir (TFV), and zidovudine (AZT), NNRTIs doravirine (DOR), efavirenz (EFV), and rilpivirine (RPV), INSTIs bictegravir (BIC), cabotegravir (CAB), and dolutegravir (DTG), and PIs atazanavir (ATV), darunavir (DRV), and lopinavir (LPV). Mutations selected in vitro were compared with those selected in persons receiving the same ARV. RESULTS: Twenty-seven studies described 89 experiments of wildtype isolates passaged with 3TC, FTC, ABC, TFV, or AZT; sixteen studies described 89 experiments passaged with EFV, RPV, or DOR; eleven studies described 76 experiments passaged with the INSTIs BIC, CAB, or DTG; six studies described 33 experiments passaged with ATV, LPV, or DRV. With several exceptions, mutations selected in two or more experiments were among the most common mutations selected in persons receiving the same ARV. CONCLUSIONS: We created a database of published ARV in vitro selection experiments. Mutations emerging from these experiments generally predict those observed in persons receiving the same ARV. However, there are notable differences in mutation frequencies between in vitro and in vivo settings.
RESUMEN
ABSTRACT Brazil is a huge continental country with striking geographic differences which are well illustrated in the HIV/AIDS epidemic. Contrasting with the significant decline in the national AIDS detection rate in the last decade, a linear growth has been reported in the Northern region. Despite its public health and epidemiologic importance, there is scarce HIV-1 molecular data from Northern Brazil. This scoping review summarizes recent epidemiologic data with special emphasis on HIV-1 genetic diversity and antiretroviral drug resistance mutations in patients from the seven Northern states of Brazil. Studies from the Northern Brazil on different HIV-1 genomic regions, mostly pol (protease/reverse transcriptase) sequences of naïve/antiretroviral treated adults/children were retrieved from PubMed/MEDLINE electronic database. These studies indicate a consistent molecular profile largely dominated by HIV-1 subtype B with minor contribution of subtypes F1 and C and infrequent detection of other subtypes (A1, D, K), recombinants (BF1, BC), circulating recombinant forms (CRF) as the new CRF90_BF1 and CRF02_AG-like, CRF28-29_BF-like, CRF31_BC-like, and a potential new CRF_BF1. This pattern indicates a founder effect of subtype B and the introduction of non-B-subtypes and recombinants probably generated in the Southern/Southeastern regions. In naïve populations transmitted drug resistance (TDR) can impact the outcome of first-line antiretroviral treatment and prophylactic/preventive regimens. In the Northern region TDR rates are moderate while patients failing highly active antiretroviral therapy (HAART) showed high prevalence of acquired drug resistance mutations. The limited HIV-1 molecular data from Northern Brazil reflects the great challenges to generate comprehensive scientific data in isolated, underprivileged areas. It also highlights the need to invest in local capacity building which supported by adequate infrastructure and funding can promote robust research activities to help reduce the scientific asymmetries in the Northern region. Currently the impacts of the overwhelming COVID-19 pandemic on the expanding HIV/AIDS epidemic in Northern Brazil deserves to be closely monitored.
Asunto(s)
Humanos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , VIH-1/genética , COVID-19 , Filogenia , Brasil , Resistencia a Medicamentos , Análisis de Secuencia de ADN , Farmacorresistencia Viral/genética , Pandemias , SARS-CoV-2 , Genotipo , MutaciónRESUMEN
Antiretroviral drug-resistance mutations compromise the successful treatment of children and adolescents infected with human immunodeficiency virus type 1 (HIV-1). We describe the clinical, virological, and immunological follow-up of a cohort of children and adolescents perinatally infected with HIV-1 treated at Hospital Estadual de Doenças Tropicais Dr. Anuar Auad HDT, in Central Brazil, after therapeutic failure related to drug resistance mutations. We analyzed the results of the genotypic test (protease codons 199 and reverse transcriptase codons 1325) performed from 2003 to 2015. The ARV susceptibility profile was analyzed according to Stanford HIV drug resistance database. A total of 65 patients (median age of 10 years; range, 18 m18 y) with therapeutic failure (after a median of 55 months of follow up; range, 9 m13 y) and plasma levels of HIV-1 RNA greater than 1,000 copies/mL which were included and demonstrated mutations in: nucleoside reverse transcriptase inhibitors (NRTIs), 98.5%; non nucleoside reverse transcriptase inhibitors (NNRTIs), 75.4%; and protease inhibitors (PI), 44.6%. The most frequent NRTI mutations were found in codon T215 (83.1%) with a predominance of T215Y (56.9%), followed by M184V (69.3%). In the NNRTI class, mutations K103N (36.9%) and 190A (23.1%) were predominant, and, in the protease, mutations 54VL (35.4%) and 82ASTL (32.3%) were found in approximately the same proportion, with a predominance of the M54V mutation. These results demonstrate the high levels of resistance to different classes of antiretrovirals in HIV-infected children and adolescents and the importance of genotypic resistance tests in this population
Asunto(s)
Inhibidores de Proteasas , Resistencia a Medicamentos , VIH , Genotipo , MutaciónRESUMEN
With the rapid scale-up in use of antiretroviral therapy (ART), monitoring thequality of care and factors that may lead to emergence of HIV drug resistance(HIVDR) is an important focus point for programme managers. The National AIDSControl Organisation of India embarked on strengthening the ART programme forcontinuous quality improvement (CQI), using defined quality-of-care indicators(QCIs), including World Health Organization (WHO) early-warning indicators(EWIs) for HIVDR. In this feasibility study, done during July 2014, an integratedQCI and EWI tool developed by WHO India was pilot tested across 18 purposivelyselected ART centres. At seven ART centres, the EWI 1 target of >90% on-timepill pick-up was achieved for adult patients, while among the paediatric age group(<15 years old) it was not achieved by any centre. EWI 2 (retention of patientsin ART care at 12 months after initiation) showed that two centres had retentionof both adult and paediatric patients of >85% at 12 months of ART, while 11centres had retention between 75% and 85%. EWI 3 (pharmacy stock-out) foradult and paediatric patients showed that 11 ART centres reported a minimumof one stock-out for the first-line ART drugs in the reporting period, while EWI 4targets (pharmacy dispensing practices) were achieved by all the centres, for bothadults and children. Average retention in care at 6, 12 and 24 months after ARTinitiation was 82%, 77% and 71%, respectively. This feasibility study showed thatEWI analyses were much simpler to conduct if information was sought only forpatients receiving ART, for whom the quality of record-keeping is better and moreconsistent. The activity has highlighted the need for improved quality of recordkeeping at the facilities and implementation of specific interventions to ensurebetter patient follow-up. After modifications, use of the tool will be phased in acrossall the ART centres in India.
Asunto(s)
IndiaRESUMEN
Background: In 2011, at least 34 million people live with HIV. HIV vertical infected children require close follow-up from all the way through diagnosis to treatment and management of complications. Case summary: This is the case of a 13-year-old male patient with HIV (vertical transmission) diagnosed at 4 months old. His HIV diagnosis was made in the context of opportunistic manifestations of immunodeficiency because his mother did not access prenatal check-ups. He developed AIDS sequelae such as spastic paraparesia derived from HIV myelopathy and CMV retinitis due to immunodeficiency; these diseases presented in first two years of life. After three years from HAART initiation, the patient was exposed to inadequate HAART (ritonavir without another protease inhibitor), and experienced a first change of therapy due to virological failure. Subsequent treatment regimens a sum of 7 presented failures in their formulation and this, along with delays due to administrative issues, led to the patient developing multiresistance to most of antiretrovirals given. The patient died mainly from multiorganic failure due to HIV and wasting syndrome. Conclusion: Congenital HIV is a fundamental issue in public health. It is a preventable disease, and perinatal management, including diagnosis and treatment, is a must. Treatment has demonstrated effectiveness when it is given with proper schemes and adherence. Administrative barriers led to failures in treatment and this affects the prognosis of any patient with HIV. This case is an example that highlights the relationship between virological and clinical failures with health system barriers, in HIV infected children. Managing gaps in diagnosis, antiretroviral administration, and follow up of HIV infected children translates into the prognosis of future adolescents and adults.
Antecedentes: en 2011, al menos 34 millones de personas viven con el VIH. Los niños infectados con VIH vertical requieren un seguimiento cercano desde el diagnóstico hasta el tratamiento y el tratamiento de las complicaciones. Resumen del caso: este es el caso de un paciente masculino de 13 años con VIH (transmisión vertical) diagnosticado a los 4 meses de edad. Su diagnóstico de VIH se realizó en el contexto de manifestaciones oportunistas de inmunodeficiencia porque su madre no accedió a controles prenatales. Desarrolló secuelas del SIDA tales como la paraparesia espástica derivada de la mielopatía por VIH y la retinitis por CMV debido a la inmunodeficiencia; estas enfermedades se presentaron en los primeros dos años de vida. Después de tres años desde el inicio de HAART, el paciente estuvo expuesto a TARGA inadecuado (ritonavir sin otro inhibidor de proteasa) y experimentó un primer cambio de terapia debido a falla virológica. Los regímenes de tratamiento subsiguientes -una suma de 7- presentaron fallas en su formulación y esto, junto con retrasos debidos a problemas administrativos, llevaron al paciente a desarrollar una resistencia múltiple a la mayoría de los antirretrovirales administrados. El paciente murió principalmente por falla multiorgánica debido al VIH y al síndrome de desgaste. Conclusión: el VIH congénito es un problema fundamental en la salud pública. Es una enfermedad prevenible y el tratamiento perinatal, incluidos el diagnóstico y el tratamiento, es obligatorio. El tratamiento ha demostrado efectividad cuando se administra con esquemas y adherencia adecuados. Las barreras administrativas condujeron a fallas en el tratamiento y esto afecta el pronóstico de cualquier paciente con VIH. Este caso es un ejemplo que destaca la relación entre las fallas virológicas y clínicas con las barreras del sistema de salud, en los niños infectados por el VIH. La gestión de las brechas en el diagnóstico, la administración de antirretrovirales y el seguimiento de los niños infectados por el VIH se traduce en el pronóstico de futuros adolescentes y adultos.
Asunto(s)
Humanos , VIH , Pediatría , Resistencia a MedicamentosRESUMEN
Background: India has rapidly scaled up its programme for antiretroviral therapy(ART). There is high potential for the emergence of HIV drug resistance (HIVDR),with an increasing number of patients on ART. It is not feasible to perform testingfor HIVDR using laboratory genotyping, owing to economic constraints. This studypiloted World Health Organization (WHO) early-warning indicators (EWIs) forHIVDR, and quality-of-care indicators (QCIs), in four ART clinics in Pune city.Methods: A retrospective study was conducted in 2015, among four ART clinicsin Pune city, India. The data on four standardized EWIs (EWI 1: On-time pill pickup, EWI 2: Retention of patients in ART care at 12 months after initiation, EWI 3:Pharmacy stock-out, EWI 4: Pharmacy dispensing practices) and three QCIs(QCI 1: Regularity in CD4 testing in patients taking ART, QCI 2: Percentage ofpatients initiating ART within 30 days of medical eligibility, QCI 3: Percentage ofpatients initiating ART within 30 days of initiation of anti-tuberculosis therapy) wereabstracted into WHO Excel HIV data abstractor tools, from the patient recordsfrom April 2013 to March 2014.Results: All four ART clinics met the EWI 4 target (100%) for ART dispensingpractices. The target for EWIs on-time pill-pick (EWI 1 >90%) and pharmacy stockouts (EWI 3: no stock-outs, 100%) were achieved in one clinic. None of the clinicsmet the EWI 2 target for retention in care at 12 months (>90%) and the overallretention was 76% (95% confidence interval: 73% to 79%). The targets for QCI 1and QCI 2 (>90% each) were achieved in one and two clinics respectively. Noneof the clinics achieved the target for QCI 3 (>90%).Conclusion: ART dispensing practices (EWI 4) were excellent in all clinics. Effortsare required to strengthen retention in care and timely pill pick-up and ensurecontinuity of clinic-level drug supply among the programme clinics in Pune city.The clinics should focus on regularity in testing CD4 count and timely initiation ofART
Asunto(s)
IndiaRESUMEN
Objective@#The purpose of this survey was to estimate the prevalence of viral load (VL) suppression and emergence of HIV drug resistance (HIVDR) among individuals receiving antiretroviral therapy (ART) for 36 months or longer in Viet Nam using a nationally representative sampling method.@*Methods@#The survey was conducted between May and August 2014 using a two-stage cluster design. Sixteen ART clinics were selected using probability proportional to proxy size sampling, and patients receiving ART for at least 36 months were consecutively enrolled. Epidemiological information and blood specimens were collected for HIV-1 VL and HIVDR testing; HIVDR was defined by the Stanford University HIVDR algorithm.@*Results@#Overall, 365 eligible individuals were recruited with a mean age of 38.2 years; 68.4% were men. The mean time on ART was 75.5 months (95% confidence interval [CI]: 69.0–81.9 months), and 93.7% of the patients were receiving non-nucleoside reverse transcriptase inhibitor-based regimens. Of the 365 individuals, 345 (94.7%, 95% CI: 64.1–99.4%) had VL below 1000 copies/mL and 19 (4.6%, 95% CI: 2.8-–7.5) had HIVDR mutations.@*Discussion@#Our nationally representative survey found a high level of VL suppression and a low prevalence of HIVDR among individuals who received ART for at least 36 months in Viet Nam. Continued surveillance for HIVDR is important for evaluating and improving HIV programs.